Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026

An ongoing Phase 2a trial in mildly infected diabetic foot ulcers is expected to deliver topline data in the first quarter of 2027.

Rhea-AI Summary

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) announced research on its antimicrobial candidate Nu-3 for presentation at IDWeek on October 22, 2026.

Laboratory testing showed activity against Gram-positive, Gram-negative and multidrug-resistant bacteria, with eradication within minutes for tested pathogens and activity against biofilm organisms. Serial-passage testing showed only a slight increase in minimum inhibitory concentration, the amount needed to stop bacterial growth, against Staphylococcus aureus and Escherichia coli, versus a 600- to 2,000-fold increase for ciprofloxacin. Nu-3 is in an ongoing Phase 2a trial for mildly infected diabetic foot ulcers; the company expects topline data in the first quarter of 2027.

4 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 2a trial is underway in mildly infected diabetic foot ulcers; topline data are expected in first-quarter 2027.
• Minor pointNu-3 laboratory testing showed bacterial eradication within minutes for tested pathogens, including multidrug-resistant bacteria.
• Minor pointSerial-passage testing showed only slight inhibitory-concentration increases for Nu-3 versus 600- to 2,000-fold increases for ciprofloxacin.
• Minor pointBiofilm testing showed Nu-3 activity against biofilm organisms.

Negative

• None.

Argus 15 min delay 17 alerts

-9.96% vs previous close $0.52 last price 10.7x rel. volume Open Argus

Details

Market move: LABT -9.96% vs previous close. Nu-3 antimicrobial data

-35.7% Trough in 10 min

$0.42 – $0.65 Day Range

$1.23M Mkt Cap at Last Price

On Oct 21, the day this news came out, the latest delayed price for LABT is 9.96% below the previous close. Argus tracked a trough of -35.7% from its starting point during tracking. Our momentum scanner has recorded 17 alerts for this stock so far that day. The latest delayed price is $0.52. Relative volume is exceptionally heavy at 10.7x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Ciprofloxacin MIC increase: 600- to 2,000-fold increase Diabetic foot ulcers that become infected: Approximately half Infected ulcers involving resistant organisms: Estimated 15% to 25% +2 more

Ciprofloxacin MIC increase

600- to 2,000-fold increase

Comparator in serial-passage testing

Diabetic foot ulcers that become infected

Approximately half

Disease context stated in the article

Infected ulcers involving resistant organisms

Estimated 15% to 25%

Primarily methicillin-resistant Staphylococcus aureus

Trial phase

Phase 2a

Ongoing study in patients with mildly infected diabetic foot ulcers

Topline trial data

First quarter of 2027

Expected timing

Historical Context

2 past events · Latest: Sep 28

2 events

1. Sep 28

   Nu-3 laboratory data

   24h Move

   -31.1%

   Nu-3 showed activity against recent diabetic foot-ulcer isolates regardless of their drug-resistance status.

2. Sep 24

   Phase 2a trial initiation

   24h Move

   +2.5%

   The first patient was dosed in the Phase 2a Nu-3 trial for mildly infected diabetic foot ulcers.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

bactericidal, biofilm, serial-passage testing, minimum inhibitory concentration, +1 more

5 terms

bactericidal medical

"broad-spectrum and rapid bactericidal activity against Gram-positive, Gram-negative"

An agent or product that is bactericidal kills bacteria outright rather than merely stopping their growth; it reduces the number of live bacterial cells. This distinction matters to investors because bactericidal drugs, disinfectants, or medical devices can have different regulatory paths, market uses, and competitive value compared with agents that only inhibit bacteria, much like a fire extinguisher that puts out flames versus a barrier that only slows their spread.

biofilm medical

"as well as activity against biofilm organisms"

A biofilm is a thin, slimy community of microbes that stick to surfaces—like a microscopic film on a pipe or a toothbrush—held together by a self-made sticky coating. Investors care because biofilms can make infections harder to treat, reduce the effectiveness of medical devices and cleaning products, and create demand for specialized drugs, diagnostics or coatings, affecting market size, regulatory risk and a company’s ability to win approvals and customers.

serial-passage testing technical

"Serial-passage testing also demonstrated a favorable resistance profile"

Serial-passage testing is a laboratory method in which a microorganism (commonly a virus or bacterium) is grown repeatedly through successive rounds of culture or infection, with material from each round used to start the next. The procedure forces rapid cycles of replication so scientists can observe how the organism's genetic makeup, growth characteristics, or susceptibility to drugs and immune responses change over time; it is used to study adaptation, attenuation, resistance development, or stability of engineered traits. A key limitation is that changes observed under repeated laboratory passage reflect selective pressures of the experimental conditions and may not predict how the organism would evolve in natural or clinical settings.

minimum inhibitory concentration medical

"increase in minimum inhibitory concentration (MIC) values"

Minimum inhibitory concentration (MIC) is the lowest concentration of an antibiotic or other antimicrobial agent that prevents visible growth of a microorganism in a standardized laboratory test. It is determined by exposing the organism to serial dilutions of the drug under controlled conditions and observing the lowest dose that stops growth; MIC is an in vitro measure that does not directly show killing of the organism and can vary with test method, growth medium, and organism strain. Clinical interpretation of an MIC uses established breakpoints to categorize an organism as susceptible, intermediate, or resistant, but the MIC alone does not predict treatment outcome.

multidrug-resistant medical

"Gram-positive, Gram-negative and multidrug-resistant bacteria"

Multidrug-resistant describes a disease-causing organism — usually a bacterium, virus, or parasite — that no longer responds to several different medications used to treat it. For investors, this matters because it narrows treatment options, can raise costs and regulatory hurdles for new therapies, and increases demand and market value for effective drugs, diagnostics, or preventive measures, much like a stubborn weed that resists multiple herbicides and creates pressure for new solutions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Research highlights Nu-3's rapid bactericidal activity against clinically relevant resistant pathogens and its potential as a topical treatment for infected diabetic foot ulcers

SARASOTA, Fla., Oct. 21, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin^® class, today announced the presentation of research highlighting the antimicrobial profile of Nu-3, the Company's lead clinical candidate, at IDWeek 2026. IDWeek 2026 is taking place October 21-24, 2026, in Washington, D.C.

The poster, titled, "Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In-Vitro Activity Against Resistant Pathogens for the Treatment of Infected Diabetic Foot Ulcers," highlights data demonstrating that Nu-3 elicits broad-spectrum and rapid bactericidal activity against Gram-positive, Gram-negative and multidrug-resistant bacteria, with bacterial eradication occurring within minutes for tested pathogens, as well as activity against biofilm organisms. Serial-passage testing also demonstrated a favorable resistance profile, with only a slight increase in minimum inhibitory concentration (MIC) values against Staphylococcus aureus and Escherichia coli, compared with a 600- to 2,000-fold increase for ciprofloxacin.

These findings are relevant to infected diabetic foot ulcer (iDFU), where approximately half of diabetic foot ulcers become infected and an estimated 15% to 25% involve resistant organisms, primarily methicillin-resistant Staphylococcus aureus (MRSA). Nu-3 is currently being investigated in an ongoing Phase 2a clinical trial in patients with mildly infected diabetic foot ulcers. Topline data from the trial are expected in the first quarter of 2027.

"The data being presented at IDWeek reinforce the potential of Nu-3 to play an important role in addressing the growing threat of antimicrobial resistance," said Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research and Development at Lakewood-Amedex Biotherapeutics. "Nu-3's broad-spectrum and rapid bactericidal activity, combined with its low potential for resistance development, underscore its potential as a differentiated antimicrobial therapy for iDFUs. With our Phase 2a trial now underway, we look forward to building on these encouraging findings as we advance Nu-3 toward our goal of providing a potential new, topically delivered treatment option for patients with difficult-to-treat infections."

Details of the presentation are as follows: 

Event:	IDWeek 2026
Presentation Title:	Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In-Vitro Activity Against Resistant Pathogens for the Treatment of Infected Diabetic Foot Ulcers
Poster Session:	Novel Agents
Date/Location:	October 22, 2026, 12:15 PM - 1:30 PM, ET, Poster Hall B-C

About Nu-3
Nu-3 is Lakewood-Amedex Biotherapeutics Inc.'s lead product being developed for the topical treatment of mildly infected diabetic foot ulcers (iDFU). Nu-3 belongs to a novel class of antimicrobials being developed by Lakewood-Amedex Biotherapeutics Inc. called the Bisphosphocin^® class, which possess a unique mechanism of action that enables rapid elimination of a broad spectrum of bacteria, including resistant pathogens and biofilms.

About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin^® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.'s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin^® platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results may not be predictive of future results; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the company's SEC filings, including under "Risk Factors." Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update them except as required by law.

Contact

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com 

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-presents-data-highlighting-nu-3s-broad-spectrum-antimicrobial-activity-and-low-potential-for-resistance-at-idweek-2026-302914893.html

SOURCE Lakewood-Amedex Biotherapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lakewood-Amedex's Nu-3 laboratory research show at IDWeek 2026?

Nu-3 showed antimicrobial activity against Gram-positive, Gram-negative and multidrug-resistant bacteria, with eradication within minutes for tested pathogens. Serial-passage testing showed only a slight increase in minimum inhibitory concentration against Staphylococcus aureus and Escherichia coli, compared with a 600- to 2,000-fold increase for ciprofloxacin.

When does Lakewood-Amedex expect Nu-3 Phase 2a trial results?

Lakewood-Amedex expects topline data in the first quarter of 2027 from its ongoing Phase 2a trial. The trial is investigating Nu-3 in patients with mildly infected diabetic foot ulcers.